MA26270A1 - Vaccin contre la variole - Google Patents

Vaccin contre la variole

Info

Publication number
MA26270A1
MA26270A1 MA27401A MA27401A MA26270A1 MA 26270 A1 MA26270 A1 MA 26270A1 MA 27401 A MA27401 A MA 27401A MA 27401 A MA27401 A MA 27401A MA 26270 A1 MA26270 A1 MA 26270A1
Authority
MA
Morocco
Prior art keywords
smallpox vaccine
smallpox
vaccine
Prior art date
Application number
MA27401A
Other languages
English (en)
Inventor
Richard A Weltzin
Thomas P Monath
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of MA26270A1 publication Critical patent/MA26270A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA27401A 2001-04-23 2003-11-17 Vaccin contre la variole MA26270A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/840,751 US6723325B1 (en) 2001-04-23 2001-04-23 Smallpox vaccine

Publications (1)

Publication Number Publication Date
MA26270A1 true MA26270A1 (fr) 2004-09-01

Family

ID=25283120

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27401A MA26270A1 (fr) 2001-04-23 2003-11-17 Vaccin contre la variole

Country Status (20)

Country Link
US (2) US6723325B1 (fr)
EP (1) EP1381389B1 (fr)
JP (1) JP4397591B2 (fr)
KR (1) KR20040063083A (fr)
CN (1) CN1527722A (fr)
AU (1) AU2002258910B2 (fr)
BR (1) BR0209145A (fr)
CA (1) CA2444747C (fr)
CZ (1) CZ305819B6 (fr)
EA (1) EA007656B1 (fr)
ES (1) ES2546612T3 (fr)
HK (1) HK1062804A1 (fr)
HU (1) HU228401B1 (fr)
IL (2) IL158549A0 (fr)
MA (1) MA26270A1 (fr)
MX (1) MXPA03009711A (fr)
NZ (1) NZ529265A (fr)
PL (1) PL212117B1 (fr)
WO (1) WO2002085411A1 (fr)
ZA (1) ZA200309084B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723325B1 (en) * 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
WO2006113927A2 (fr) * 2005-04-20 2006-10-26 University Of Washington Peptides de la vaccine immunogenes et procedes d'utilisation de ces peptides
RU2541784C2 (ru) * 2006-11-07 2015-02-20 Санофи Пастер Байолоджикс Ко. Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения
KR100859345B1 (ko) * 2006-12-12 2008-09-19 씨제이제일제당 (주) 세포배양에 의해 두창 백신을 생산하는 방법 및 그에 의해생산된 두창 백신
WO2012142529A2 (fr) * 2011-04-15 2012-10-18 Genelux Corporation Souches clonales de virus atténués de la vaccine et leurs procédés d'utilisation
RU2496149C1 (ru) * 2012-06-19 2013-10-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ оценки противооспенной активности лечебно-профилактических препаратов
AU2017353868C1 (en) 2016-11-02 2024-06-06 David Evans Synthetic chimeric poxviruses
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3177862A1 (fr) 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Systemes ameliores pour therapie virale oncolytique a mediation cellulaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
JPS60202827A (ja) * 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5614193A (en) * 1991-11-14 1997-03-25 The United States Of America As Represented By The Secretary Of The Army Hantavirus vaccine
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6723325B1 (en) * 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine

Also Published As

Publication number Publication date
ES2546612T3 (es) 2015-09-25
CN1527722A (zh) 2004-09-08
EP1381389A1 (fr) 2004-01-21
EP1381389A4 (fr) 2004-07-28
EP1381389B1 (fr) 2015-08-26
IL158549A0 (en) 2004-05-12
PL373958A1 (en) 2005-09-19
HUP0303878A3 (en) 2010-01-28
ZA200309084B (en) 2005-01-26
BR0209145A (pt) 2005-04-19
NZ529265A (en) 2006-04-28
CA2444747A1 (fr) 2002-10-31
CZ305819B6 (cs) 2016-03-30
CZ20033184A3 (cs) 2004-04-14
US6723325B1 (en) 2004-04-20
PL212117B1 (pl) 2012-08-31
AU2002258910B2 (en) 2007-10-25
EA007656B1 (ru) 2006-12-29
EA200301151A1 (ru) 2004-10-28
US7115270B2 (en) 2006-10-03
WO2002085411A1 (fr) 2002-10-31
HK1062804A1 (en) 2004-11-26
JP2005503126A (ja) 2005-02-03
US20060153873A1 (en) 2006-07-13
CA2444747C (fr) 2018-04-17
JP4397591B2 (ja) 2010-01-13
IL158549A (en) 2009-07-20
MXPA03009711A (es) 2005-03-07
HU228401B1 (en) 2013-03-28
HUP0303878A2 (hu) 2004-03-01
KR20040063083A (ko) 2004-07-12

Similar Documents

Publication Publication Date Title
NO20035208D0 (no) Nytt vaksine preparat
DK1427444T3 (da) West-nil-vaccine
ATE553775T1 (de) Impstoffzusammesetzung
IS7831A (is) Bóluefni
NO20031483L (no) Vaksine
NO20024172L (no) Vaksine
IS7297A (is) Streptococcis Pneumoniae bóluefni
NO20033882L (no) Vaksine
GB0407935D0 (en) Vaccine
DZ3219A1 (fr) Vaccin
EP1423141A4 (fr) Vaccin
GB0121171D0 (en) Vaccine
IS8325A (is) Bóluefni
DE60328408D1 (de) Impfstoff
NO20051561D0 (no) Vaksine
MA26270A1 (fr) Vaccin contre la variole
DE10290185D2 (de) Tumorvakzine
GB0308691D0 (en) Vaccine preparations
ATE392435T1 (de) Ostertagia-impfstoff
GB0215621D0 (en) Improved poxvirus vaccines
NO20011990D0 (no) Kreftvaksine
GB0115496D0 (en) Vaccine
GB0124137D0 (en) Vaccine
GB0130823D0 (en) Vaccine
GB0106589D0 (en) Vaccine